Our 2007 MCT article "Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma" (1) highlights the antitumor mechanism and response of an experimental model of anaplastic large cell lymphoma (ALCL) to an experimental agent now known as crizotinib. Anaplastic large cell lymphoma is characterized by the expression of an oncogenic NPM-ALK fusion protein, believed to be a key oncogenic driver of this disease. The near complete inhibition of NPM-ALK activity in experimental ALCL was consistent with a robust inhibition of downstream signal transduction, induction of apoptosis, and a complete regression of ALCL in vivo. This was the first report that inhibition of ALK activity was associated with dramatic antitumor activity in ALK positive models and the first indicating that crizotinib is an inhibitor of ALK. This non-clinical (4), crizotinib demonstrated a 57% response rate with in lung adenocarcinoma patients that tested positive for the EML4-ALK fusion event. Collectively, these clinical results indicate that ALK alterations are important genetic events in the pathogenesis of a subset of human cancers and that these cancers can be effectively treated with inhibitors of ALK activity. Clinical studies with crizotinib are ongoing and continue to evaluate the activity of crizotinib in ALK positive patient populations.
